Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A known ✓ | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL1669798 | 1.00 | KDM4E (0.46) | KDM4ERECQLADRA2AADRA2BADRA2C | |
| SCHEMBL1670230 | 0.90 | ADRA2A (0.44) | KDM4EADRA2AADRA2BADRA2CMMP2 | |
| Fumaric Acid SCHEMBL1672620 | 0.84 | ADRA2A (0.49) | KDM4ERECQLADRA2AADRA2BADRA2C | |
| Fumaric Acid SCHEMBL1672617 | 0.84 | ADRA2A (0.49) | KDM4ERECQLADRA2AADRA2BADRA2C | |
| SCHEMBL1670132 | 0.75 | ADRA2A (0.51) | KDM4EADRA2AADRA2BADRA2CMMP2 | |
| SCHEMBL1670420 | 0.74 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CSMN1; SMN2ALDH1A1 | |
| Fumaric Acid SCHEMBL1672611 | 0.73 | ADRA2A (0.51) | KDM4EADRA2AADRA2BADRA2CSMN1; SMN2 | |
| Fumaric Acid SCHEMBL1672613 | 0.73 | ADRA2A (0.51) | KDM4EADRA2AADRA2BADRA2CSMN1; SMN2 | |
| SCHEMBL1670164 | 0.72 | ADRA2A (0.59) | KDM4EADRA2AADRA2BADRA2CSMN1; SMN2 | |
| Fumaric Acid SCHEMBL1669737 | 0.69 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CSMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3584237-B1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN INC (US) | 2020-12-09 | — | — | EP | claimed |
| EP-2486009-B1 | 2H-PYRROL-5-AMINE DERIVATIVES AS ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN INC (US) | 2019-08-21 | — | — | EP | claimed |
| US-20150209351-A1 | Alpha Adrenergic Receptor Modulators | ALLERGAN, INC. | 2015-07-30 | — | — | US | claimed |
| US-9040532-B2 | Alpha adrenergic receptor modulators | ALLERGAN, INC. (US) | 2015-05-26 | — | — | US | claimed |
| US-20120208821-A1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN, INC (US) | 2012-08-16 | — | — | US | claimed |
| EP-2486009-A1 | 2H-PYRROL-5-AMINE DERIVATIVES AS ALPHA ADRENERGIC RECEPTOR MODULATORS | Allergan, Inc. (US) | 2012-08-15 | — | — | EP | claimed |
| WO-2011044229-A1 | 2H-PYRROL-5-AMINE DERIVATIVES AS ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2011-04-14 | — | — | WO | claimed |
| EP-3584237-B1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN INC (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-2486009-B1 | 2H-PYRROL-5-AMINE DERIVATIVES AS ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-9522150-B2 | Alpha adrenergic receptor modulators | ALLERGAN, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20150209351-A1 | Alpha Adrenergic Receptor Modulators | ALLERGAN, INC. | 2015-07-30 | — | — | US | disclosed |
| US-9040532-B2 | Alpha adrenergic receptor modulators | ALLERGAN, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20120208821-A1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN, INC (US) | 2012-08-16 | — | — | US | disclosed |
| EP-2486009-A1 | 2H-PYRROL-5-AMINE DERIVATIVES AS ALPHA ADRENERGIC RECEPTOR MODULATORS | Allergan, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011044229-A1 | 2H-PYRROL-5-AMINE DERIVATIVES AS ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209351-A1 | Alpha Adrenergic Receptor Modulators | ADRB1, ADRB2, ADRA2C | MEN1 2178/4885KMT2A 3759/4885KDM4E 4505/4885 |
| US-20120208821-A1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ADRB1, ADRB2, ADRA2C | MEN1 2178/4885KMT2A 3759/4885KDM4E 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.